An observational study of the effect of two thiazolidinediones on blood lipid levels: Rosiglitazone and pioglitazone in routine clinical practice

Current Therapeutic Research - Clinical and Experimental

Volumn 65, Issue 2, 2004, Pages 149-160

  Griffis, Deborah ^a   McLaughlin, Trentnt ^b   Dirani, Riad ^c   Thwaites, Rob ^c  

^a AdvancePCS   (United States)

^b Wolters Kluwer   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

pioglitazone; rosiglitazone; thiazolidinedione

Indexed keywords

EID: 32644456208     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(04)90029-X     Document Type: Article

References (32)

1. Skyler J.S., and Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev 18 Suppl 3 (2002) S21-S26
2. Eschwege E., Simon D., and Balkau B. The growing burden of diabetes in the world population. IDF Bvlletia 42 (1997) 14-19
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). published correction appears in. Lancet 354 (1999) 602
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). published correction appears in. Lancet 352 (1998) 837-853
6. Lebovitz H.E. Treating hyperglycemia in type 2 diabetes: New goals and strategies. Cleve Clin J Med 69 (2002) 809-820
7. Gutowski C. Understanding new pharmacologic therapy for type 2 diabetes. Nurse Pract 24 (1999) 15-18
8. Gutowski C. Understanding new pharmacologic therapy for type 2 diabetes. Nurse Pract 24 (1999) 21-22
9. Gutowski C. Understanding new pharmacologic therapy for type 2 diabetes. Nurse Pract 24 (1999) 24-25
10. Goldstein B.J. Differentiating members of the thiazolidinedione class: A focus on efficacy. Diabetes Metab Res Rev 18 Suppl 2 (2002) S16-S22
11. Schneider R., Egan J., Houser V., et al. Pioglitazone is effective in the treatment of patients with type 2 diabetes. Diabetes 48 Suppl 1 (1999) A109 Abstract
12. Lebovitz H.E., Dole J.F., Patwardhan R., et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. published corrections appear in. J Clin Endocrinol Metab 86 (2001) 1659
13. Lebovitz H.E., Dole J.F., Patwardhan R., et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. published corrections appear in. J Clin Endocrinol Metab 2 (2002) iv
14. Lebovitz H.E., Dole J.F., Patwardhan R., et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. published corrections appear in. J Clin Endocrinol Metab 86 (2001) 280-288
15. Parker J.C. Troglitazone: The discovery and development of a novel therapy for the treatment of type 2 diabetes mellitus. Adv Drug Deliv Rev 54 (2002) 1173-1197
16. Austin M.A. Plasma triglyceride as a risk factor for coronary heart disease: The epidemiological evidence and beyond. Am J Epidemiol 129 (1989) 249-259
17. Mimura K., Umeda F., Hiramatsu S., et al. Effect of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11 (1994) 685-691
18. Schwartz S., Raskin P., Fonseca V., and Graveline J.F. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338 (1998) 861-866
19. Ghazzi M.N., Perez J.E., Antonucci T.K., et al., Troglitazone Study Group. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46 (1997) 433-439
20. Khan M.A., St Peter J.V., and Xue J.L. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25 (2002) 708-711
21. Vestergaard H., Lund S., and Pedersen O. Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. J Intern Med 250 (2001) 406-414
22. Freed M.I., Ratner R., Marcovina S.M., et al., Rosiglitazone Study 108 Investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90 (2002) 947-952
23. Gegick C.G., and Altheimer M.D. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice. published correction appears in. Endocr Pract 7 (2001) 330
24. Gegick C.G., and Altheimer M.D. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice. published correction appears in. Endrocr Pract 7 (2001) 162-169
25. Boyle P.J., King A.B., Olansky L., et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clin Ther 24 (2002) 378-396
26. Lebovitz H.E. Differentiating members of the thiazolidinedione class: A focus on safety. Diabetes Metab Res Rev 18 Suppl 2 (2002) S23-S29
27. National Institutes of Health (NIH) National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol is Adults (ATP III) (2002), NIH National Heart, Lung, and Blood Institute, Bethesda, Md NIH publication 02-5215
28. D'Hoore W., Sicotte C., and Tilquin C. Risk adjustment in outcome assessment: The Charlson comorbidity index. Methods Inf Med 32 (1993) 382-387
29. Lebovitz H.E., Dole J.F., Patwardhan R., et al., Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 280-288
30. Phillips L.S., Grunberger G., Miller E., et al., Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. published correction appears in. Diabetes Care 24 (2001) 973
31. Phillips L.S., Grunberger G., Miller E., et al., Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. published correction appears in. Diabetes Care 24 (2001) 308-315
32. Hirose H., Kawai T., Yamamoto Y., et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51 (2002) 314-317